H.C. Wainwright analyst Oren Livnat raised the firm’s price target on ANI Pharmaceuticals to $53 from $50 and keeps a Buy rating on the shares following the "strong" Q4 results. The analyst views the company’s 2023 guidance as likely conservative.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ANIP:
- ANI Pharmaceuticals sees FY23 adjusted EPS $2.09-$2.53, consensus $2.62
- ANI Pharmaceuticals reports Q4 non-GAAP EPS 76c, consensus 67c
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Guggenheim starts ANI Pharmaceuticals at Buy on cortrophin gel’s potential
- ANI Pharmaceuticals initiated with a Buy at Guggenheim
